Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
This clinical trial is for men and women with myelofibrosis.
The purpose of this study is to test the safety and tolerability of INCB057643 in combination with ruxolitinib on people with myelofibrosis.
INCB057643 is experimental, which means that it is being tested and is not approved by the United States Food and Drug Administration (FDA). Ruxolitinib has been approved by the FDA for the treatment of different rare blood disorders called Myelofibrosis (MF), including Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF), Post Essential Thrombocythemia Myelofibrosis (PET-MF), Polycythemia vera and acute, and chronic GvHD.
There are 2 parts to this study. Part 1 participants will receive INCB057643 and Part 2 participants will receive a combination of INCB057643 and ruxolitinib dose escalation and expansion.
It is estimated that an individual will receive study drug administration for approximately 9 months. The overall study duration is estimated to be approximately 24 months. This includes up to 28 days for screening, study drug administration in consecutive 28-day cycles as long as participants are receiving benefits and have not met any criteria for study withdrawal, and 30 to 35 days for safety follow-up after the last dose of the study drug.
Detailed eligibility will be reviewed when you contact the study team.